Mirtazapin Orion (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Orion, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral administration. It works by modulating norepinephrine and serotonin pathways and is primarily prescribed for the management of major depressive disorder in adult patients, helping to alleviate depressive symptoms and improve mood.

GNH USA supplies Mirtazapin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled sourcing and reliable logistics for global healthcare providers.

Mirtazapine is used in the treatment of depressive disorders, acting on noradrenergic and serotonergic pathways. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Treatment‑resistant depression (adjunct therapy): may enhance response when combined with other antidepressants. - Depressive episodes with insomnia: helps improve sleep quality while treating depression.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Sedation or drowsiness. - Increased appetite leading to weight gain. - Dry mouth. - Constipation.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Hepatic dysfunction. - Emergence of suicidal thoughts, especially during early treatment.

When prescribing mirtazapine, clinicians should consider several safety measures. - Monitor weight: patients may experience significant weight gain. - Assess for sedation: may impair driving or operating machinery. - Screen for suicidal ideation: especially during initial weeks. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce efficacy. - Anticholinergic agents: may exacerbate dry mouth. - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for serotonin syndrome.